Annalisa Jenkin’s previous roles include Head of Global Research & Development at Merck Serono, during which time cilengitide was one of the drug development programs. Prior to this, she held several leadership roles at Bristol Myers-Squibb (BMS) from 1997 to 2011, most recently serving as Senior VP and Head of Global Medical Affairs. Earlier in her career, Dr Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Annalisa is a member of the board of directors of Dimension Therapeutics, Ardelyx, Inc., Biothera Pharmaceutical Inc., Viventia Bio, Inc., iOX Therapeutics Limited, and MedCity, and previously served as a board member of Prosensa Holding N.V. (acquired by BioMarin Pharmaceutical). She also is a committee member of the Science Board to the U.S. Food & Drug Administration, and a member of the European Union Commission’s Scientific Panel for Health. She also serves on the boards of Women in Bio and the Center for Talent Innovation (U.K.), is an executive committee member of Springboard Enterprises, and is on the Advisory Panel of the Healthcare Businesswomen’s Association. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.